Objective: The present study was undertaken to evaluate and compare the effects of ramipril which is an angiotensin converting enzyme inhibitor (ACEI) and telmisartan, an angiotensin receptor blocker (ARB) in streptozotocin (STZ) induced diabetic nephropathy in rats.
Materials and Methods: The diabetic rats were divided into four groups of six each. They were administered test drugs such as telmisartan (10mg/kg), ramipril (5mg/kg) or vehicle for 16 weeks. Blood samples were collected for the estimation of blood glucose, blood urea nitrogen, serum creatinine. Urine was collected for the measurement of protein and determination of creatinine clearance.
Results: STZ diabetic rats exhibited marked hyperglycemia, proteinuria, uremia and reduction in creatinine clearance. Telmisartan pretreatment reduced blood glucose level after 8 weeks which was not observed with ramipril. Both telmisartan and ramipril significantly altered the remaining parameters towards normal.
Conclusion: Although telmisartan is superior to ramipril with respect to blood glucose lowering effect, the renoprotective action of telmisartan appears to be similar to ramipril. Therefore telmisartan may be used as an alternative to ramipril in the treatment of hypertensive diabetic patients with nephropathy.
STZ, telmisartan, ramipril, diabetic nephropathy.